NASDAQ: AVXLAnavex Life Sciences Corp Stock
$3.39-0.02 (-0.59%)
Updated Apr 25, 2024
AVXL Price
$3.39
Fair Value Price
$1.89
Market Cap
$278.36M
52 Week Low
$3.25
52 Week High
$10.45
P/E
-6.16x
P/B
2.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$29M
Beta
1.4
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AVXL Overview
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVXL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVXL ($3.39) is overvalued by 79.1% relative to our estimate of its Fair Value price of $1.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVXL ($3.39) is not significantly undervalued (79.1%) relative to our estimate of its Fair Value price of $1.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVXL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVXL due diligence checks available for Premium users.
Be the first to know about important AVXL news, forecast changes, insider trades & much more!
AVXL News
Valuation
AVXL fair value
Fair Value of AVXL stock based on Discounted Cash Flow (DCF)
Price
$3.39
Fair Value
$1.89
Overvalued by
79.10%
AVXL ($3.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVXL ($3.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVXL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVXL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.16x
Industry
15.41x
Market
40.97x
AVXL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.05x
Industry
5.8x
AVXL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVXL's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.6M
Profit Margin
0%
AVXL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$148.1M
Liabilities
$12.5M
Debt to equity
0.09
AVXL's short-term assets ($148.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVXL's short-term assets ($148.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVXL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVXL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.3M
Investing
$0.0
Financing
$59.0k
AVXL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVXL vs Biotech Stocks
Anavex Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.